Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astellas Pharma : and LabCentral Announce Golden Ticket Winners, Helping Emerging Biotechs Accelerate Growth of Innovative Science

10/09/2020 | 09:17am EST

CAMBRIDGE - Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., 'AVM'), a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage life-sciences startups, today announced AXONIS Therapeutics, Inc. and Tenza as the winners of the Astellas-sponsored 'Golden Ticket Competition'.

A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral's state-of-the-art lab facility in Cambridge, Massachusetts, as well as access to Astellas' research and development (R&D) capabilities and business leaders.

AXONIS and Tenza were chosen for the strength of the innovation in their approach, the therapeutic potential of their research and alignment of their novel technological platforms with Astellas' research and development (R&D) Focus Areas.

'In awarding these Golden Tickets, we are reinforcing Astellas' ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide,' said Maruyama, President, AVM. 'We applaud the efforts of AXONIS and Tenza in the advancement of potential treatments for CNS disorders and mucosal disease respectively, and we look forward to helping them realize their potential in these complex and underserved therapeutic areas.'

AXONIS Therapeutics, Inc. is advancing research for spinal cord injury and other neurological disorders. AXONIS is currently conducting pre-clinical studies on its novel small molecule technology. The technology is being studied to reactivate spared neural tissue at a spinal cord injury site and help alleviate neuropathic pain and spasticity through upmodulation of KCC2 protein activity.

'We are honored to be awarded an Astellas Golden Ticket,' said Joanna Stanicka, Ph.D., CEO of AXONIS. 'Combining Astellas' CNS disorder expertise with LabCentral's exciting incubator space will further validate our KCC2-targeted programs that we are investigating to treat not only spinal cord injuries but a host of other neurological conditions in areas of high unmet patient need.'

Tenza is developing orally available therapeutics for mucosal disease by engineering probiotic microbes to produce and deliver drugs directly to gut tissue - with the goal of boosting bioavailability and therapeutic efficacy while reducing systemic side effects.

'Gaining access to Astellas' R&D and clinical expertise is a fantastic opportunity, for which we are most grateful,' said Anik Debnath, Ph.D., co-Founder & CEO of Tenza. 'In conjunction with the lab space from LabCentral, it will allow us to accelerate the pre-clinical development of our lead programs and pursue additional indications that leverage our platform's capabilities across mucosal disease more broadly.'

'We are very pleased by Astellas' support of LabCentral and the Golden Ticket program,' said Johannes Fruehauf, LabCentral co-Founder and President. 'A Golden Ticket gives these emerging companies a leg up in their development process by giving access not only to our supportive environment, but also some of the brightest pharmaceutical minds in the industry at Astellas. Both are integral to these companies realizing their dream to help patients in their chosen field of research.'

Both AXONIS and Tenza will continue their residence at LabCentral with the next year sponsored by Astellas. Both will be closely supported by the team from AVM and the Astellas Biomedical Innovation Hub organizations in the Boston area to maximize their progress.

About the Golden Ticket Competition

Astellas' sponsorship of the Golden Ticket Competition follows AVM obtaining Gold Sponsorship of LabCentral in October of 2019. Companies awarded an Astellas Golden Ticket will gain one year's priority admission or renewal to LabCentral's state-of-the-art laboratory and access to Astellas' R&D scientists and business leaders. The decision to award any Golden Ticket, and the assessments underlying such decision, are solely within the judgment of Astellas and LabCentral, and are not subject to any objection or appeal.

About Astellas Venture Management LLC

AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 20 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research.

About Astellas

Astellas Pharma, Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

About LabCentral

A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high-potential life sciences and biotech start-ups. Operating a total of 100,000 square-feet in the heart of Kendall Square in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 70 start-ups comprising approximately 500 scientists and entrepreneurs.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Jarrod Aldom

Tel: +1 508-714-6817

Email: jarrod.aldom@astellas.com

(C) 2020 Electronic News Publishing, source ENP Newswire

11/18Japan shares fall as virus surge, firmer yen weigh
11/17ASTELLAS PHARMA : to Present New Data on Gilteritinib in FLT3 Mutation-Positive ..
11/09ASTELLAS PHARMA INC. : - XTANDI Approved by China NMPA for the Treatment of Non-..
11/02ASTELLAS PHARMA : Completes Acquisition of iota Biosciences
10/30Japan stocks fall, post biggest weekly loss in 3 months on virus worries
10/29Japanese shares slump on virus worries, mixed earnings
10/28ASTELLAS PHARMA : Receives U.S. FDA Fast Track Designation for ASP5354, an Inves..
10/27ASTELLAS PHARMA INC. : half-yearly earnings release
10/23ASTELLAS PHARMA : ITI Announces Promotion of Dr. Tim Coleman to SVP, Operations ..
10/21ASTELLAS PHARMA INC. : - U.S. FDA Grants Fast Track Designation for ASP0367/MA-0..
More news
Sales 2021 1 273 B 12 177 M 12 177 M
Net income 2021 194 B 1 853 M 1 853 M
Net cash 2021 444 B 4 246 M 4 246 M
P/E ratio 2021 15,6x
Yield 2021 2,58%
Capitalization 3 028 B 28 935 M 28 957 M
EV / Sales 2021 2,03x
EV / Sales 2022 1,84x
Nbr of Employees 15 883
Free-Float 99,2%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 287,50 JPY
Last Close Price 1 630,00 JPY
Spread / Highest target 96,3%
Spread / Average Target 40,3%
Spread / Lowest Target 4,29%
EPS Revisions
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
MERCK & CO., INC.-11.73%203 111
PFIZER INC.-6.59%202 993
NOVARTIS AG-13.38%198 168